On 04 June 2026, InSilico Medicine Cayman TopCo (“INSILICO”) submitted its monthly return to the Hong Kong Stock Exchange, covering the period ended 31 May 2026. The filing shows no changes to authorised or issued share capital during the month.

Authorised Share Capital • Authorised ordinary shares remained at 1.27 billion, each with a par value of USD 0.0000005, translating to total authorised capital of USD 635.

Issued Shares and Public Float • Issued ordinary shares held steady at 572.40 million with zero treasury shares outstanding. • The company confirmed compliance with the minimum public-float requirement of 15 percent for this share class.

Equity Incentive Schemes • Pre-IPO share options outstanding declined marginally by 2,224 to 27.77 million after lapses; no new shares were issued and no funds were raised from option exercises. Outstanding pre-IPO options represent up to 23.92 million shares. • The Post-IPO Share Option Scheme, approved on 15 December 2025, had no movements during the month, retaining a capacity of 24.16 million shares that may be issued upon future grants or exercises. • Pre-IPO Restricted Share Units (RSUs) carry a potential 2.52 million shares, while the Post-IPO RSU Scheme recorded no activity in May.

Other Securities • The issuer reported no warrants, convertible instruments, or other arrangements leading to share issuance during the month.

With no share issuances, repurchases, or treasury transactions recorded, INSILICO’s share capital base and public-float position remained unchanged in May 2026.